Health
Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage
Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's recommendations and support for emerging federal policies expected to dramatically improve treatment access for millions of Americans living with obesity. The OMA commends the Centers for Medicare and Medicaid Services (CMS) and pharmaceutical partners,...
About this update from Novo Nordisk A/s Class B
[{"type":"text","content":"Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's recommendations and support for emerging federal policies expected to dramatically improve treatment access for millions of Americans living with obesity. The OMA commends the Centers for Medicare and Medicaid Services (CMS) and pharmaceutical partners, including Eli Lilly and Novo Nordisk, for collaborating on initiatives that reinforce the recognition of obesity as a chronic disease requiring comprehensive medical treatment.","length":672,"tagName":"p"},{"type":"text","content":"The OMA's position focuses on several critical areas of expansion and improvement, urging policymakers to ensure equitable, affordable, and seamless access to care. While much is likely to change in the coming months to years, the following represents an initial preliminary OMA Position Statement, with a planned follow-up at a later date when policies are more definitive.","length":378,"tagName":"p"},{"type":"text","content":"Medicare Coverage Pilots & Affordability (Starting 2026) The OMA supports the initial pilot of GLP-1 obesity medication coverage through Medicare Part D beginning in 2026, with eligibility based on BMI and obesity complications.","length":232,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Affordable Copay: Eligible Medicare beneficiaries who qualify under the demonstration project may pay a flat $50 monthly copay for injectable GLP-1 therapies, regardless of dose.","length":178,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expansion Urged: The OMA urges a transition to a mandatory, permanent program in 2027 to ensure long-term, broad access.","length":120,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":298,"olType":false},{"type":"text","content":"Streamlined Prior Authorization (Preauthorization) The OMA urges CMS to approve obesity medications based on clinical criteria and without any preauthorization to reduce administrative burdens.","length":193,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"If Required, Make It Seamless: If preauthorization remains necessary, the OMA calls for a fric...